News | May 14, 2026
Bayer posts strong Q1 2026 results as Crop Science surge lifts earnings & outlook
Net income more than doubled to 2.763 billion euros, while core earnings per share climbed 12.9 percent to 2.71 euros
Net income more than doubled to 2.763 billion euros, while core earnings per share climbed 12.9 percent to 2.71 euros
The company informed stock exchanges that the appellate authority has set aside the GST demand along with applicable interest and penalty
Growth was supported by stronger COVID vaccine sales and expanded government supply agreements in international markets
The deals, tied to cases in the US District Court for the District of Delaware, effectively extend US patent protection for VYNDAMAX until June 1, 2031
The Pharmaceuticals portfolio and pipeline are more promising than perhaps ever before
The litigation involved multiple civil lawsuits alleging anti-competitive practices and violations of federal
In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga
Parliament clears reform bill replacing jail terms for procedural lapses with graded monetary penalties across key health laws
Moderna will appeal to the Federal Circuit to assert that its government-contractor immunity limits liability under federal law
This marks the second indication for which gumokimab has gained NDA review acceptance
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
